Albireo Pharma is a biopharmaceutical company that specializes in developing innovative bile acid modulators for the treatment of rare pediatric liver diseases, as well as other liver and gastrointestinal disorders. The company's lead product candidate, odevixibat, is currently in Phase 3 development for treating rare cholestatic liver diseases in children, including progressive familial intrahepatic cholestasis and biliary atresia. Albireo Pharma was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with a subsidiary in Gothenburg, Sweden. The company has been recognized as one of the best places to work in Massachusetts by the Boston Business Journal for two years running.
Albireo Pharma's ticker is ALBO
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 51-200 employees working at Albireo Pharma
It is albireopharma.com
Albireo Pharma is in the Healthcare sector
Albireo Pharma is in the Biotechnology industry
The following five companies are Albireo Pharma's industry peers: